摘要
目的:探讨辛夷散基于瞬时受体电位香草酸亚型1(TRPV1)通路治疗变应性鼻炎(AR)大鼠的疗效和作用机制.方法:将70只SD大鼠随机分为空白组,模型组,辛夷散低、中、高剂量组,激动剂组,阳性药组,每组10只.除空白组外,其余各组大鼠均采用卵清蛋白(OVA)致敏方法制作AR大鼠模型.造模成功后,除空白组外,其余各组采用相应药物治疗,且均OVA滴鼻维持致敏.治疗前后观察行为学评分,HE染色观察鼻黏膜组织形态学变化;ELISA检测血清白细胞介素(IL)-4、IL-5、IL-13、免疫球蛋白E(IgE)水平;ELISA检测鼻黏膜组织中TRPV1、P物质(SP)、降钙素基因相关肽(CGRP)、神经生长因子(NGF)水平.结果:与空白组比较,模型组外周血IgE、IL-4、IL-5、IL-13表达显著增多(P＜0.01),鼻黏膜TRPV1、SP、CGRP、NGF表达显著增多(P＜0.01);与模型组比较,辛夷散各剂量组外周血IgE、IL-4、IL-5、IL-13表达显著降低(P＜0.05,P＜0.01),鼻黏膜TRPV1、SP、CGRP、NGF表达显著降低(P＜0.01);与阳性药组和激动剂组比较,辛夷散中剂量组外周血IgE、IL-4、IL-5、IL-13表达显著升高(P＜0.01),鼻黏膜TRPV1、SP、CGRP、NGF表达显著升高(P＜0.01).结论:辛夷散可能是通过调控TRPV1通路减少SP、CGRP、IL-4释放从而抑制Th2细胞过度活化,降低痒觉神经敏化,缓解鼻痒,从而治疗AR.
Abstract
Objective:To investigate the efficacy and mechanism of action of Xinyi Powder based on transient receptor potential vanilloid subfamily 1(TRPV1)pathway in the treatment of allergic rhinitis(AR)rats.Methods:A total of 70 SD rats were randomly divided into the blank group,the model group,the low,medium and high dose groups of Xinyi Powder,the agonist group and the positive drug group,with 10 rats in each group.Except for the blank group,all the rats in each group were sensitized by ovalbumin(OVA)to create a rat model of AR.After successful modeling,corresponding drugs for treatment was gaved and sensitization was maintained by OVA nasal drops in all groups except the blank group.Behavioral scores were observed before and after treatment,and morphological changes of nasal mucosa tissue were observed by HE staining;serum IL-4,IL-5,IL-13,IgE levels were detected by ELISA;TRPV1,SP,CGRP,NGF levels in nasal mucosa tissue were detected by ELISA.Results:Compared with the blank group,the model group showed increased expression of IgE,IL-4,IL-5,IL-13 in peripheral blood(P＜0.01),and TRPV1,SP,CGRP,NGF in nasal mucosa(P＜0.01);compared with the model group,the three dose groups decreased expression of IgE,IL-4,IL-5,IL-13 in peripheral blood(P＜0.05,P＜0.01),and TRPV1,SP,CGRP,and NGF in nasal mucosa(P＜0.01);compared with the positive drug group and the agonist group,there was a statistically increase in peripheral blood IgE,IL-4,IL-5,IL-13 expression in the medium dose group of Xinyi Powder(P＜0.01),and increase in nasal mucosal TRPV1,SP,CGRP,and NGF expression in the medium dose group of Xinyi Powder(P＜0.01).Conclusion:Xinyi Powder may reduce the release of SP,CGRP and IL-4 by modulating the TRPV1 pathway thereby inhibiting the overactivation of Th2 cells,decreasing itch nerve sensitization,relieving nasal itch,and treating AR.
基金项目
南京中医药大学与企业合作横向研究课题(2020)(012009200055)
NETL
NSTL
万方数据